Skip to main content
CriticalFDAfda-F-1740-2017CHEMICAL EXPOSURE

Ocho-Rios Jamaican Nice Mild Curry Powder, 4 oz. Manufactured by Oriental Packing Co.

⚠ Critical Alert — Stop Using Immediately

This product has been flagged with severe risks (chemical exposure). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.

Category
Units Affected
14,000
Recall Date
December 7, 2016
Issuing Agency
Hazard
Chemical Exposure

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1740-2017.

Product contains lead.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1740-2017.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Oriental Packing Co., Inc. or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1740-2017.

Oriental Packing Co., Inc.

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Oriental Packing Co., Inc. Recall FAQ

Oriental Packing Co., Inc. is the subject of a food safety report: Ocho-Rios Jamaican Nice Mild Curry Powder, 4 oz. Manufactured by Oriental Packing Co.. The notice was published on December 7, 2016 by the U.S. Food and Drug Administration (FDA). Approximately 14,000 units are potentially affected.